The CYPHER® (Cordis, Johnson & Johnson) sirolimus-eluting stent and the TAXUS® (Boston Scientific) paclitaxel-eluting stent have been extensively evaluated and have been proven to be significant novel tools for the treatment of coronary artery disease. Several sirolimus derivatives have already emerged, receiving CE Mark approval. However, in the future, it is likely that drugs presently under investigation will address additional mechanisms associated with neointimal formation, either as single agents or in combination with antiproliferative compounds. Concurrently, alterations on stent platform design (helicoidal, open-closed cell), coatings (biodegradable, bioabsorbable, nanoporous) and polymers are being explored.
Alaide Chieffo, Young H. Kim, Emanuele Meliga, Seung J. Park, Marco Valgimigli, Valeria Magni, Renata Rogacka, Seong W. Park, Duk W Park, Flavio Airoldi, Matteo Montorfano, Patrick W. Serruys, Antonio Colombo
Bernard Chevalier, Patrick W. Serruys, Sigmund Silber, Eulogio Garcı́a, Harry Suryapranata, Karl Eugen Hauptmann, William Wijns, Gerhard Schüler, Farzin Fath‐Ordoubadi, Stephen G. Worthley, Leif Thuesen, Ian T. Meredith, Marco Bressers, Hirofumi Nagai, Dragica Paunovic
Discussion(0)
No comments yet. Be the first to comment.